Filing Flows › GSK (GSK) › Q3 2024
GSK (GSK) Q3 2024 earnings results (third quarter 2024)
6-K filed Oct 30, 2024
GSK (GSK) reported revenue of $8.0B for the third quarter 2024 (Q3 2024), -2% from a year earlier. Operating margin was 2.4%, net earnings $65.0M (0.8% of revenue).
GSK, Q3 2024: revenue $8.0B (-2% year over year), operating margin 2.4%, net earnings $65.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.0B | — | -2% |
| Gross profit | $5.6B | — | -4% |
| Operating profit | $189M | — | -90% |
| Net earnings | $65.0M | — | -96% |
What changed
Revenue was £8.0B in Q3 2024, down 2% year over year. Vaccines ex COVID was the largest line at 33% of revenue.
Gross margin was 70.1%, down 2.0 points from a year earlier. Operating profit was £0.19B, a 2.4% margin (down 21.6 points year over year). Operating expenses grew 38% against a revenue fall of 2%. The fastest-growing cost line was Other operating costs (+204%). Net earnings were −£0.06B. The effective tax rate was -1.6%.
Questions
What was GSK's revenue in the third quarter 2024?
GSK (GSK) reported revenue of $8.0B for the third quarter 2024 (Q3 2024), -2% from a year earlier.
Was GSK profitable in the third quarter 2024?
Operating profit was $189M (2.4% of revenue) and net earnings $65.0M.
Source: GSK 6-K on SEC EDGAR.